Introduction
This article tries to give an overview of the current international situation of pharmaceutical parallel trade (PPT). Parallel trade is not limited to pharmaceutical products (see later in the article, but because of the special nature of pharmaceuticals, which differentiate them from "normal" consumer goods, there are not only economical facts to be given, but legal considerations and political implications to be remembered. This becomes clear-among others-when analyses of the same phenomenon come to completely different, sometimes even contradictory results, as it is the case with the recent economic studies on this subject, which will be shown next. Part of the reason for such different results could lie in some shortcomings in economic theory as well as in the limited availability of appropriate data.
By giving an economic, legal, and political outline, the reader of this article should be enabled to understand the international status quo of PPT as well as the different interests, policies, and aims of the individual market participants.
Definition of PPT
Parallel trade is a phenomenon well known internationally: A common definition is worded in the fundamental work of Arfwedson [1] as follows:
Re-importation (or parallel trade as it is known in Europe) occurs when products protected by patent, trademark or copyright are first placed into circulation on one market, then (re-) imported into a second market without the authorization of the original owner of the intellectual property rights (IPRs).
Arfwedson concludes his definition with the remark that "Myriad products are re-imported, including automobiles, clothing, perfume and other consumer goods." This shows to us that parallel trade is an almost ubiquitous phenomenon (at the end of the last decade, it was estimated, for instance, that up to 20% of the market for Coca-Cola in the UK was served by parallel imports coming from wholesalers in other European countries [2]).
Price Differentials As Driving Forces
What are the reasons of this situation? Apparently, there must be a strong driver for the international, almost ubiquitous appearance of parallel trade: profit, or better said, price differences allowing firms to make profits in exploiting the possibility of arbitrage if transaction costs are low enough. Wherever there are sufficient price differentials to make movement of goods economically viable, and a regulatory framework, which permits it, parallel trade comes into action. In the case of pharmaceuticals, Maskus [3] obtained international ex-manufacturer's prices and sales data for major molecules (20 brand-name drugs) in 14 countries, for which he calculated average per dosage prices (see Table 1 ). In the same study, he used data from the Swedish Medical Products Agency for a basket of 90 brand-name drugs (see Table 2 ) to make a European price comparison.
Maskus [3] identified the price differentials on the international as well as on the European level, with low-price countries like Greece and Spain, and highprice countries like the UK or Switzerland. Maskus found that prices in many drugs were relatively low in numerous developed countries, e.g., Canada, Italy, and Spain, whereas in other less developed countries, e.g., Mexico, Brazil, and South Africa, they were relatively high, which he explained mainly with the existence of significant price controls in countries with low prices.
Costs of marketing pharmaceutical parallel imports (PPIs) are high-it is a tightly regulated industry with rigorous standards and regulatory requirements, but there are still enough margins to make it worthwhile, and parallel trade in pharmaceuticals has grown consistently in Europe. The market size has been estimated at a value of EUR 4.2 billion in 2004 [4], a development of between EUR 2.6 billion in 2001 and EUR 5.8 billion in 2006 [5] , respectively.
Legal Background

Exhaustion and Its Different Forms
The definition of parallel import in Deardorff's Glossary of International Economics [6] is as follows:
Trade that is made possible when the owner of intellectual property causes the same product to be sold in different countries for different prices. If someone else imports the low-price good into the high-price country, that is a parallel import.
The legal basis of parallel import lies in the European principle of exhaustion and the American "firstsale doctrine," which are explained in the following: Exhaustion was developed in Germany in the early 20th century by the pioneering work of Josef Kohler [7] . Its American equivalent, the "first-sale doctrine," was established at roughly the same time by a decision of the US Supreme Court in 1908 [8] .
Exhaustion is one of the basic principles of intellectual property (IP) law worldwide. The concept of exhaustion can be explained in the following: Once trademarked goods are put on the market by the trademark owner or with his consent, the trademark owner is no longer allowed further to control the distribution of those goods. He has "exhausted" his distribution right by the first sale of the goods. There are basically three different forms and concepts of exhaustion:
1. National exhaustion means that the trademark right (or patent or copyright) is exhausted only Parallel Trade: Switzerland, the EU, and the United States
